On November 12th, the pharmaceutical company shenyang xingqi pharmaceutical (300573.SZ) announced that its product Cyclosporine Eye Drops (Ⅱ) recently obtained the phase IV clinical research report on the safety and effectiveness of Cyclosporine Eye Drops (Ⅱ) in the treatment of dry eye.
The company's Cyclosporine Eye Drops (Ⅱ) has obtained the "Pharmaceutical Registration Certificate". As of the date of the announcement, according to the website of the National Medical Products Administration, the company's Cyclosporine Eye Drops (Ⅱ) is the only domestically approved Cyclosporine ophthalmic preparation for the treatment of dry eye.
The study is a multicenter, prospective clinical trial. A total of 1999 subjects underwent a 24-week medication observation to evaluate the safety and effectiveness of Cyclosporine Eye Drops (Ⅱ) for patients with dry eye. The results of the study showed that Cyclosporine Eye Drops (II) had good overall safety, good tolerability, and could effectively improve dry eye symptoms and signs.
